Janssen Korea to market Remicade

Published: 2011-07-01 06:59:00

Updated: 2011-07-01 06:59:00

Starting in July 1, Janssen Korea will have a marketing right for Remicade as a high-stake fight between Merck and Johnson & Johnson over the rights to a pair of lucrative arthritis medicines - Remicade and Simponi - was finally resolved in April.

Under the deal, Merck will relinquish exclusive marketing rights to the drugs in various locales: Canada, Central and South America, the Middle Ea...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.